AUS
NZ
UK
CA
USA
IND
Highlights
Recce Pharmaceuticals Ltd (ASX:RCE) completes shortfall placement to finalise broader capital raising initiative
Proceeds to fund key clinical programs focused on antibiotic-resistant infection treatments
Trials include diabetic foot infections in Indonesia and bacterial skin infections in Australia
The biotechnology sector on the ASX 200 was in focus as Recce Pharmaceuticals Ltd (ASX:RCE) confirmed the completion of its shortfall placement. The development comes amid wider investor interest in companies working on solutions to combat antibiotic-resistant infections. As a company listed on both the Australian and US markets (OTC:RECEF), Recce’s recent financing update positions it within a growing segment of biotechs targeting critical infectious disease indications.
The placement finalised the company’s broader capital raising effort. Shares were issued to existing institutional and sophisticated shareholders at a price in line with the original entitlement offer disclosed earlier this year.
Completion of Full Capital Raising Program
Recce Pharmaceuticals concluded its capital raise with the shortfall placement, following previous funding rounds including a private placement and the entitlement offer. The funding strategy was supported by a lead manager and co-lead manager, with the objective of advancing clinical work without delays.
The company stated the outcome of this final step supports its ability to continue progressing its synthetic anti-infective development programs. The capital will be directed towards ongoing and upcoming trials, regulatory submissions, and other business activities related to pipeline advancement.
Advancing Phase 3 Clinical Trials in Infectious Disease
A major focus of the newly secured funds is the support of two pivotal Phase 3 clinical trials. These trials aim to address infections that continue to present a major burden on global health systems.
The first of these is a study on diabetic foot infections (DFI) in Indonesia. This trial is intended to serve as a registrational study and is regarded as an essential initiative for Recce’s lead topical treatment candidate.
The second is focused on acute bacterial skin and skin structure infections (ABSSSI), conducted in Australia. The new trial builds on previous Phase 2 results that met predefined endpoints. The company expects both programs to provide essential clinical data that will inform future regulatory and commercial steps.
Focus on Clinical Pipeline and Regulatory Planning
In addition to the Phase 3 programs, the proceeds will fund broader development activities. These include preparing and submitting an Investigational New Drug (IND) application to the US Food and Drug Administration. Recce also indicated that working capital and operational costs tied to ongoing research will be covered under this allocation.
The company’s synthetic anti-infective candidates, RECCE® 327, RECCE® 435, and RECCE® 529, remain central to its innovation efforts. These candidates are designed to address both bacterial and viral infections and form the core of Recce’s pipeline strategy.
Biotech Advancements Shape Sector Developments
The completion of Recce’s capital raise comes at a time when funding in the biotechnology space remains selective. Recce’s ability to close this transaction, despite prevailing headwinds, highlights continued institutional engagement in the area of synthetic anti-infectives.
Market participants tracking the biotech segment will monitor the progress of Recce Pharmaceuticals Ltd (ASX:RCE) as it pursues clinical and regulatory milestones. The company’s advancement contributes to broader sectoral activity within the ASX 200, where health and life sciences remain a key focus amid global challenges tied to antimicrobial resistance.
